Mustang Bio deal with St Jude on 'bubble boy disease'

15 August 2018

USA-based Mustang Biotech (Nasdaq: MBIO) has entered into a partnership and exclusive license deal with St Jude Children’s Research Hospital for the development of a first-in-class ex vivo lentiviral gene therapy for children with X-linked severe combined immunodeficiency (X-SCID), or bubble boy disease.

The news seems not to have inspired investors, as the company’s shares fell 4.47% to $5.99 on Tuesday, though that may be to do with financial results and update that were published the same day.

The potentially curative therapy is being evaluated by St Jude and others in a Phase I/II trial in infants under two, the world’s first lentiviral gene therapy trial for infants with X-SCID, and by the National Institutes of Health in a Phase I/II trial in patients over the age of two.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK